How to buy Angion Biomedica stock | $15.44

Angion Biomedica Corp is a biotechnology business based in the US. Angion Biomedica shares (ANGN) are listed on the NASDAQ and all prices are listed in US Dollars. Angion Biomedica employs 66 staff and has a trailing 12-month revenue of around 0.00.

Angion Biomedica stock price (NASDAQ: ANGN)

Use our graph to track the performance of ANGN stocks over time.

Angion Biomedica shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$15.44
52-week range	$10.50 - $26.30
50-day moving average	$12.33
200-day moving average	$15.49
Wall St. target price	$59.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Angion Biomedica shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Angion Biomedica stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Angion Biomedica Corp by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Angion Biomedica price performance over time

Historical closes compared with the close of $15.44 from 2021-05-28

1 week (2021-07-26)	N/A
1 month (2021-07-06)	36.76%
3 months (2021-05-06)	7.82%
6 months (2021-02-02)	N/A

1 year (2020-08-02)	N/A
2 years (2019-08-02)	N/A
3 years (2018-08-02)	N/A
5 years (2016-08-02)	N/A

Angion Biomedica financials

Revenue TTM	$2.4 million
Gross profit TTM	$-37,287,000
Return on assets TTM	-116.52%
Return on equity TTM	0%
Profit margin	0%
Book value	$3.12
Market capitalisation	$324.2 million

TTM: trailing 12 months

Shorting Angion Biomedica shares

There are currently 300,721 Angion Biomedica shares held short by investors – that's known as Angion Biomedica's "short interest". This figure is 11.3% up from 270,103 last month.

There are a few different ways that this level of interest in shorting Angion Biomedica shares can be evaluated.

Angion Biomedica's "short interest ratio" (SIR)

Angion Biomedica's "short interest ratio" (SIR) is the quantity of Angion Biomedica shares currently shorted divided by the average quantity of Angion Biomedica shares traded daily (recently around 102635.15358362). Angion Biomedica's SIR currently stands at 2.93. In other words for every 100,000 Angion Biomedica shares traded daily on the market, roughly 2930 shares are currently held short.

To gain some more context, you can compare Angion Biomedica's short interest ratio against those of similar companies.

• Cortexyme (CRTX.US): 11.55
• Millendo Therapeutics (MLND.US): 0.98
• Atara Biotherapeutics (ATRA.US): 13.18

However Angion Biomedica's short interest can also be evaluated against the total number of Angion Biomedica shares, or, against the total number of tradable Angion Biomedica shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Angion Biomedica's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Angion Biomedica shares in existence, roughly 10 shares are currently held short) or 0.0137% of the tradable shares (for every 100,000 tradable Angion Biomedica shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Angion Biomedica.

Find out more about how you can short Angion Biomedica stock.

Angion Biomedica share dividends

We're not expecting Angion Biomedica to pay a dividend over the next 12 months.

Angion Biomedica overview

Angion Biomedica Corp. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York. .

Frequently asked questions

What percentage of Angion Biomedica is owned by insiders or institutions?
Currently 26.57% of Angion Biomedica shares are held by insiders and 18.262% by institutions. How many people work for Angion Biomedica?
Latest data suggests 66 work at Angion Biomedica. When does the fiscal year end for Angion Biomedica?
Angion Biomedica's fiscal year ends in December. Where is Angion Biomedica based?
Angion Biomedica's address is: 51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553